Since uncontrolled LDL-c presented a significant risk of developing cardiovascular diseases, it lacked adequate treatment despite changes in the patients’ lifestyle and the use of the maximum tolerated dose of statins. However, now that it addresses the pressing need for medical attention, the oral drug Bemdac will offer a new line of treatment for patients with uncontrolled levels of LDL-c.
Often referred to as bad cholesterol Since it is deposited on the walls of blood vessels, LDL-C increases the chances of health problems such as heart attack or stroke.
Currently uncontrolled LDL-c leads to an imbalance of lipids, including cholesterol, LDL-c, triglycerides, and high-density lipoproteins (HDL), commonly known as dyslipidemia. Citing various studies, Zydus Life Sciences on Friday stated that eight out of 10 Indians are dyslipidemic and 112 million adults suffer from high levels of LDL-c.
In addition, seven out of 10 patients with dyslipidemia who are taking statins continue to suffer from uncontrolled LDL-c. Additionally, 5.4 million Indians are intolerant to statin therapy. However, Bemdac’s bempedoic acid has also shown good results in patients who cannot tolerate statins and those who do not respond to statins.
As Zydus already has several leading brands to address cardiac care and dyslipidemia, including Atorva, Clopitorva, Zyrova and Pivasta, Bemdac is now an important addition to the company’s portfolio of medicines to manage dyslipidemia and cholesterol, said the managing director of Zydus Lifesciences, Dr. Sharvil Patel.
For example, the company’s brand, Atorva, is the market leader for atorvastatin with a market share of 18.4%, ranking second in terms of market share in the statin segment at Rs 2,162 crore , according to the AWACS Report of February 2022.